Pharma
Commented by Armin Schulz on December 2nd, 2025 | 07:00 CET
The demographic clock is ticking: How Bayer, Vidac Pharma, and Novo Nordisk are positioning themselves in the billion-dollar battle for our health
The demographic clock is ticking inexorably. An aging society brings with it a flood of widespread diseases such as heart disease, cancer, and diabetes. Each one is a billion-dollar market that is pushing healthcare systems to their limits. As costs explode, brutal, cut-throat competition is emerging. The winner will not be the one with the most pills, but the one with the most effective solutions to the greatest medical and economic challenges of our time. Today, we take a look at how Bayer, Vidac Pharma, and Novo Nordisk plan to shape the future.
Read
Commented by André Will-Laudien on November 27th, 2025 | 07:55 CET
Black Friday: DAX explodes, and biotech is back in vogue: Watch out for 100% gains at Bayer, Vidac Pharma, and Novo Nordisk
The stock market has managed to break out of its consolidation phase, and the upward trend is continuing toward the end of the year. There are signs of hope for the Leverkusen-based pharmaceutical company Bayer, and Vidac Pharma is moving into the primary segment of the Düsseldorf over-the-counter market. The well-known Novo Nordisk, whose share price has been destroyed, is experiencing its fourth sell-off in three months. Some analysts are now turning positive. Investors should now be aware that prices in the biotech sector have fallen so low that even minor news items are enough to cause prices to skyrocket. Especially during the year-end portfolio adjustments, prices often reach absurd levels. We help you navigate the thicket of valuations.
Read
Commented by Fabian Lorenz on November 25th, 2025 | 07:45 CET
Buy recommendation and major order: Evotec, Nordex, Desert Gold
Are more than 100% share price gains in Nordex still not enough? Apparently not, according to analysts. In addition, the wind turbine manufacturer has secured a major order. Will the rally continue? Analysts believe that Desert Gold shares have the potential to rise by well over 100%. In their view, Desert Gold may be on the verge of one of the most significant gold discoveries in West Africa in recent years, none of which is reflected in the current share price. And what is Evotec doing? The share is trading at its lowest level since 2016. The milestone payments in the current year do not appear to be enough for investors. What do analysts say?
Read
Commented by Fabian Lorenz on November 17th, 2025 | 07:10 CET
Out of BioNTech? Into Evotec and Vidac shares? What is going on with Johnson & Johnson?
Big news in biotech: Pfizer is selling its entire stake in German biotech champion BioNTech. Should investors consider doing the same? Meanwhile, Vidac Pharma is providing more and more reasons for a price explosion. The Company is developing a novel cancer therapy and has received approval to begin phase 2 clinical trials in Germany. It is also reportedly in talks with Johnson & Johnson. Might the pharmaceutical giant even make a move? Evotec, on the other hand, has recently sent mixed signals. Another milestone payment is ringing the cash register, and insider transactions are drawing attention. Yet the stock is trading at a multi-year low.
Read
Commented by Armin Schulz on November 14th, 2025 | 07:20 CET
Cancer will become curable - and these stocks could then be priceless: Evotec, Vidac Pharma, and Bayer
Cancer remains one of the greatest medical challenges of our time - but at the same time, it is creating business opportunities worth billions. The oncology market is literally exploding with annual growth of 10.8%, driven by aging societies and groundbreaking therapeutic approaches. Artificial intelligence is revolutionizing diagnostics, personalized medicine is making previously incurable tumors treatable, and digital platforms are dramatically accelerating drug development. While patients benefit from tailored treatments, investors sense big business opportunities. Today, we analyze Evotec, Vidac Pharma, and Bayer for their positioning in this future market.
Read
Commented by Armin Schulz on November 13th, 2025 | 07:25 CET
Underrated stocks? A look at the growth drivers of Novo Nordisk, Planethic Group, and Puma
When prices fall, strategic investors sense their biggest opportunity. In the calm before the next upswing, there are undervalued gems that are ready for their turnaround. These are established players who are not only consolidating their core businesses but are already pulling the levers for tomorrow's growth. They are transforming their business models, tapping into new markets and focusing on forward-looking technologies, often unnoticed by the broader market. This transformation is what makes companies such as pharmaceutical giant Novo Nordisk, sustainability pioneer Planethic, and sporting goods manufacturer Puma particularly interesting right now.
Read
Commented by Nico Popp on November 10th, 2025 | 07:10 CET
Patient well-being as the key to returns: Oramed Pharmaceuticals, Roche, BioNxt
Higher, faster, further – constant progress is not only important in sports. The economy and science are also all about continuous innovation and improvement. Biotechnology combines both areas. We show how new, patient-centered approaches can capture market share and also create added value for investors. To this end, we take a look at the Swiss pharmaceutical company Roche, show how the Israeli biotech company Oramed has learned from setbacks, and how BioNxt Solutions is securing promising patents with innovative dosage forms.
Read
Commented by Fabian Lorenz on November 7th, 2025 | 07:00 CET
Takeover battle between Novo Nordisk and Pfizer! Is BioNxt Solutions the next target?
Who will acquire Metsera? That is currently the subject of dispute between Novo Nordisk and Pfizer. Both pharma giants are seeking access to a new generation of metabolic therapies through the acquisition - treatments that have the potential to transform the billion-dollar market for obesity and diabetes care. Novo Nordisk views Metsera's drug pipeline as a complement to its GLP-1-based preparations, while Pfizer is trying to finally gain a foothold in the market after several setbacks. The takeover battle illustrates that big pharma companies are willing to dig deep into their pockets for innovations. This makes BioNxt Solutions a potential takeover candidate. The Company is not only working on innovations in the field of multiple sclerosis and obesity, but on an entire platform technology.
Read
Commented by André Will-Laudien on November 6th, 2025 | 07:10 CET
Novo Nordisk calculating carefully, Evotec facing potential takeover? Clinical trial and up-listing at Vidac!
The stock market is showing some turbulence in the biotech sector. Unlike the big growth stocks on the NASDAQ, there is still urgent catching-up to do here. Some figures, such as those from Novo Nordisk and Evotec, still give reason for concern. The situation is quite different at Vidac Pharma, where an up-listing to the primary market is on the horizon and a clinical trial is about to begin! Plenty of material for investors' dreams to grow. We calculate where an investment is worthwhile!
Read
Commented by Fabian Lorenz on November 5th, 2025 | 07:10 CET
Millions for BioNTech and Evotec! But drug development is costly! Is NetraMark the next takeover target?
NetraMark scores again. The Company's AI has convinced yet another biopharma company and is increasingly shaping up as a potential takeover target. The new client will use NetraAI to optimize its clinical trial, cutting both time and costs. The high expense of drug development is clear: BioNTech invested EUR 565 million into its pipeline last quarter. However, the German biotech leader can afford this thanks to billions in its coffers. Analysts still recommend buying the stock. By contrast, even a million-dollar payment from a partner could not give Evotec shares any real momentum. Could today’s figures finally spark a turnaround?
Read